All SGLT-2 inhibitors found promising for diabetes management in Indian settings: JAPI Medha Baranwal11 Jun 2022 6:00 AM GMTMaharashtra: SGLT2 Inhibitors could be considered as an add-on to all antidiabetic agents currently used for diabetes management in the Indian...
Dapagliflozin action on HFrEF not impacted by frailty: Data from DAPA-HF trial Medha Baranwal6 May 2022 4:30 AM GMTUK: Findings from a post hoc analysis of the DAPA-HF trial suggests that the protective effects of dapagliflozin in patients having heart failure with...
Dapagliflozin safe in hospitalized patients with COVID-19 with preserved or reduced kidney function Dr. Kamal Kant Kohli2 May 2022 4:15 AM GMTWashington, DC: In a recent randomized clinical trial of hospitalized patients with COVID-19 and cardio-metabolic risk factors, the sodium-glucose...
Dapagliflozin associated with improved outcomes in heart failure patients regardless of frailty Dr. Kamal Kant Kohli26 April 2022 4:15 AM GMTA post-hoc analysis of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) randomized control trial found that...
NPPA fixes retail prices of 15 formulations, ceiling price of Framycetin Ruchika Sharma19 April 2022 10:36 AM GMTNew Delhi: National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India has fixed retail prices of 15...
Add on Dapagliflozin exhibits inconsequential antidiabetic effect in kids with type 2 diabetes Medha Baranwal16 April 2022 5:45 AM GMTUSA: In an Intention-to-treat analysis of children, adolescents, and young adults with type 2 diabetes who received dapagliflozin with the standard of...
Dapagliflozin effective in treating type 1 diabetes Dr. Nandita Mohan26 Feb 2022 12:12 PM GMTType 1 diabetes is a worrying condition as ones immune system destroys insulin-making cells in the pancreas. Recent data published in PLOS One...
Dapagliflozin a new approach in the treating patients with heart failure: DAPA – HF Trial MD Editorial Team14 Feb 2022 3:30 AM GMTCardiac health is very important as its one of the vital organs. Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an...
Diabetic nephropathy effectively treated by Dapagliflozin: DAPA-CKD Trial MD Editorial Team12 Feb 2022 3:30 AM GMTDiabetes is a chronic disease that is the leading cause of kidney failure, accounting for 44% percent of new cases. Diabetic nephropathy is a serious...
DAPA CKD Trial: Dapaglifloxin to improve diabetic nephropathy Dr. Nandita Mohan11 Feb 2022 1:26 PM GMT Diabetic nephropathy is a serious complication of type 1 diabetes and type 2 diabetes. It's also called diabetic kidney disease. In the United...
Dapagliflozin appears beneficial at various levels of Heart Failure in HFrEF patients: Study Dr. Shravani Dali10 Dec 2021 3:30 AM GMTDapagliflozin appears beneficial at various levels of Heart Failure with Reduced Ejection Fraction, according to a study published in the ...
Dapagliflozin improves kidney function in patients with diabetes patients with CKD: Lancet Medha Baranwal1 Nov 2021 3:30 AM GMTDelhi: Dapagliflozin compared with placebo significantly improves the rate of decline in kidney function in patients with chronic kidney disease...
